Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 ExpressionDigestive System Diseases, Digestive System Neoplasms, Disease Attributes, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, cancer, colonic disorder, colorectal adenocarcinoma, colorectal cancer, colorectal carcinoma, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, intestinal disorder, lung disorder, lung neoplasm, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, non-small cell lung carcinoma, non-small cell squamous lung carcinoma, pancreas disorder, pancreatic neoplasm, rectal disorder, respiratory system disorder, respiratory tract neoplasmActive, not recruitingPhase 1 / Phase 22025-04-25NCT05736731

2 results · Page 1 of 1

Swipe the table sideways for more columns.

OrganizationsLinked trials
A2 Biotherapeutics Inc.5
Tempus AI18

8 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Banner HealthGilbertUnited States6
Mayo Clinic RochesterRochesterUnited States133
MD Anderson Cancer CenterHoustonUnited States589
Moffitt Cancer CenterTampaUnited States2
NYU Langone Medical CenterNew YorkUnited States32
UCLA Medical CenterLos AngelesUnited States4
University of California San DiegoLa JollaUnited States54
Washington UniversitySt LouisUnited States182